Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Summary of Financial Information with Respect to Reportable Segments

All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is financial information with respect to the Company’s reportable segments for the periods presented:

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Segment revenues:
Software	$	30,011		$	24,052		$	63,092		$	50,392
Drug discovery		8,458			5,732			24,040			11,519
Total segment revenues	$	38,469		$	29,784		$	87,132		$	61,911
Segment gross profit:
Software	$	22,910		$	18,411		$	48,480		$	38,845
Drug discovery		(5,776	)		(6,431	)		(3,363	)		(10,701	)
Total segment gross profit		17,134			11,980			45,117			28,144
Unallocated:
Research and development		(31,123	)		(21,092	)		(58,945	)		(42,540	)
Sales and marketing		(7,428	)		(5,380	)		(14,099	)		(10,619	)
General and administrative		(22,056	)		(15,850	)		(44,189	)		(29,239	)
Gain (loss) on equity investments		11,828			—			11,828			(1,781	)
Change in fair value		(15,700	)		(4,918	)		(21,864	)		19,906
Other (expense) income		(296	)		357			32			777
Income tax expense		(33	)		(67	)		(5	)		(141	)
Consolidated net loss	$	(47,674	)	$	(34,970	)	$	(82,125	)	$	(35,493	)

Schedule of Revenues by Geographic Area

The following table sets forth revenues by geographic area for the three and six months ended June 30, 2022 and 2021:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
United States	$	27,104	$	19,676	$	57,379	$	36,581
Europe		5,106		4,246		17,751		14,791
Japan		2,966		2,914		4,523		4,449
Rest of World		3,293		2,948		7,479		6,090
	$	38,469	$	29,784	$	87,132	$	61,911